Wang Y - Search Results

1

Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.

Aghajanian C, Goff B, Nycum LR, Wang Y, Husain A, Blank S. Aghajanian C, et al. Among authors: wang y. Gynecol Oncol. 2014 Apr;133(1):105-10. doi: 10.1016/j.ygyno.2014.02.003. Epub 2014 Feb 6. Gynecol Oncol. 2014. PMID: 24508841 Clinical Trial.

2

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.

Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Aghajanian C, et al. Gynecol Oncol. 2015 Oct;139(1):10-6. doi: 10.1016/j.ygyno.2015.08.004. Epub 2015 Aug 10. Gynecol Oncol. 2015. PMID: 26271155 Free PMC article. Clinical Trial.

3

Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.

Husain A, Wang Y, Hanker LC, Ojeda B, Anttila M, Breda E, Vuylsteke P, Pujade-Lauraine E. Husain A, et al. Among authors: wang y. Gynecol Oncol. 2016 Sep;142(3):465-70. doi: 10.1016/j.ygyno.2016.05.011. Epub 2016 Jun 25. Gynecol Oncol. 2016. PMID: 27184721 Clinical Trial.

4

Regorafenib alone or in combination with high/low-dose radiotherapy plus toripalimab as third-line treatment in patients with metastatic colorectal cancer: protocol for a prospective, randomized, controlled phase II clinical trial (SLOT).

Zhou S, Wang C, Shen L, Wang Y, Zhang H, Wu R, Wang Y, Chen Y, Xuan Y, Xia F, Zhang Z, Wan J. Zhou S, et al. Among authors: wang y, wang c. Front Oncol. 2023 Oct 5;13:1274487. doi: 10.3389/fonc.2023.1274487. eCollection 2023. Front Oncol. 2023. PMID: 37869085 Free PMC article.

5

TORCH-R trial protocol: hypofractionated radiotherapy combined with chemotherapy and toripalimab for locally recurrent rectal cancer: a prospective, single-arm, two-cohort, phase II trial.

Wan J, Wu R, Fu M, Shen L, Zhang H, Wang Y, Wang Y, Zhou S, Chen Y, Xia F, Zhang Z. Wan J, et al. Among authors: wang y. Front Oncol. 2023 Nov 20;13:1304767. doi: 10.3389/fonc.2023.1304767. eCollection 2023. Front Oncol. 2023. PMID: 38053659 Free PMC article.

6

A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.

Makrakis D, Wright JL, Roudier MP, Garcia J, Vakar-Lopez F, Porter MP, Wang Y, Dash A, Lin D, Schade G, Winters B, Zhang X, Nelson P, Mostaghel E, Cheng HH, Schweizer M, Holt SK, Gore JL, Yu EY, Lam HM, Montgomery B. Makrakis D, et al. Among authors: wang y. Clin Genitourin Cancer. 2023 Apr;21(2):265-272. doi: 10.1016/j.clgc.2022.12.003. Epub 2022 Dec 23. Clin Genitourin Cancer. 2023. PMID: 36710146 Clinical Trial.

7

Risk factors for fluoropyrimidine-induced cardiotoxicity in colorectal cancer: A retrospective cohort study and establishment of a prediction nomogram for 5-FU induced cardiotoxicity.

Wang Y, Wang W, Dong H, Wang G, Chen W, Chen J, Chen W. Wang Y, et al. Among authors: wang w, wang g. Front Oncol. 2023 Mar 1;13:1017237. doi: 10.3389/fonc.2023.1017237. eCollection 2023. Front Oncol. 2023. PMID: 36937428 Free PMC article.

8

Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis.

Han Y, Wang J, Wu Y, Xu H, Wang Y, Xu B. Han Y, et al. Among authors: wang j, wang y. Curr Oncol. 2022 Nov 25;29(12):9172-9180. doi: 10.3390/curroncol29120718. Curr Oncol. 2022. PMID: 36547132 Free PMC article. Review.

9

Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study.

Xu X, Ai L, Hu K, Liang L, Lv M, Wang Y, Cui Y, Li W, Li Q, Yu S, Feng Y, Liu Q, Yang Y, Zhang J, Xu F, Yu Y, Liu T. Xu X, et al. Among authors: wang y. Nat Commun. 2024 Aug 23;15(1):7255. doi: 10.1038/s41467-024-51536-x. Nat Commun. 2024. PMID: 39179622 Free PMC article. Clinical Trial.

10

Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials.

Mao S, Yang S, Liu X, Li X, Wang Q, Zhang Y, Chen J, Wang Y, Gao G, Wu F, Jiang T, Zhang J, Yang Y, Lin X, Zhu X, Zhou C, Ren S. Mao S, et al. Among authors: wang y, wang q. Exp Hematol Oncol. 2023 Jun 9;12(1):53. doi: 10.1186/s40164-023-00417-y. Exp Hematol Oncol. 2023. PMID: 37296463 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

298,492 results

Search Page

Filters